In BMMs, pretreatment with Verbascoside at 10 µM for 2 h decreased osteoclast number by 43% compared with cells supplemented with M-CSF and RANKL. Verbascoside at 10 µM also almost completely attenuated RANKL-induced pit formation compared with cells cultured with M-CSF and RANKL; addition 4 days after RANKL stimulation suppressed osteoclast numbers without reducing pit formation. In A5 metastatic cancer cells, Verbascoside at 500 μM for 24 h suppressed MMP-2 and MMP-9 enzymatic activities. Verbascoside showed significant, dose-dependent MAO-A inhibition, with an IC50 of 3.44 ± 0.06 µM. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Verbascoside reduces osteoclast numbers in BMMs
Cell-based study · BMMs [1]
BMMs pretreated with Verbascoside at 10 µM for 2 h showed a 43% decrease in osteoclast number compared with cells supplemented with M-CSF and RANKL.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM
- Exposure duration
- for 2 h; for 7 days
- Method
- pretreated
- Vehicle
- phosphate-buffered saline (PBS)
- Co-treatment
- Other interventions in this design: M-CSF 50 ng/ml; RANKL 100 ng/ml. Compound effect isolated by the comparison: compared to cells supplemented with M-CSF and RANKL.
Methods and source locations
Compound reported in the paper: Verbascoside; Compound label in the paper: Acteoside
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Mice, Chemicals, and Laboratory Wares (S5); Results > Acteoside Inhibits Osteoclast Formation by Macrophages in a Dose-Dependent Manner (S85, S87); Figure 1 legend (S151)
the number of osteoclasts was counted: the number of osteoclasts was counted; comparator: cells supplemented with M-CSF and RANKL — Results > Acteoside Inhibits Osteoclast Formation by Macrophages in a Dose-Dependent Manner (S87); Figure 1 legend (S151)
Verbascoside suppresses enzymatic activities in metastatic cancer cells
Cell-based study · A5 metastatic cancer cells [2]
Treatment of A5 metastatic cancer cells with Verbascoside at 500 μM for 24 h suppressed MMP-2 and MMP-9 enzymatic activities.
Literature-Reported Treatment Conditions
- Treatment concentration
- 500 μM
- Exposure duration
- 24 h
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Verbascoside; Compound label in the paper: Acteoside
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Acteoside is increasingly toxic in mouse and human cancer cells (S52); Fig. 1 legend (S95)
MMP-9 and MMP-2 enzymatic activities: MMP-9 and MMP-2 enzymatic activities; comparator: not (-) — Results > Acteoside is increasingly toxic in mouse and human cancer cells (S52); Fig. 1 legend (S95)
Dose-dependent inhibition of MAO-A
Cell-based study · MAO-A [3]
Verbascoside was evaluated in a MAO-A enzyme inhibition assay with DMSO as the control. It showed significant, dose-dependent inhibitory capacity, with an IC50 of 3.44 ± 0.06 µM.
Literature-Reported Treatment Conditions
- Exposure duration
- every 5 min for 40 min
- Method
- In each well
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: Verbascoside
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.6. Neuroprotective Capacity. In Vitro Enzymatic Inhibition Capacity > 2.6.2. MAO-A Inhibition Assay (S82, S84, S85, S86); 3. Results > 3.5. Neuroprotective Capacity. In Vitro Enzymatic Inhibition Capacity > 3.5.2. MAO-A Inhibition Assay (S173)
percentage of enzyme inhibition: percentage of enzyme inhibition; comparator: 50µL of DMSO as a control — 2. Materials and Methods > 2.6. Neuroprotective Capacity. In Vitro Enzymatic Inhibition Capacity > 2.6.2. MAO-A Inhibition Assay (S85); 3. Results > 3.5. Neuroprotective Capacity. In Vitro Enzymatic Inhibition Capacity > 3.5.2. MAO-A Inhibition Assay (S173)
Treatment timing affects pit formation in BMMs
Cell-based study · BMMs [1]
A 10 µM acteoside treatment almost completely attenuated RANKL-induced pit formation by BMMs. The ability of acteoside to inhibit bone resorption depended on the timing of the treatment relative to RANKL stimulation. Acteoside (10 µM) added 4 days after RANKL stimulation did not reduce pit formation in BMMs, whereas it suppressed the number of osteoclasts formed.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM
- Exposure duration
- 7 days
- Method
- with and without acteoside
- Vehicle
- phosphate-buffered saline (PBS)
- Co-treatment
- Other interventions in this design: M-CSF 50 ng/ml; RANKL 100 ng/ml. Compound effect isolated by the comparison: vs. cells cultured with M-CSF and RANKL.
Methods and source locations
Compound reported in the paper: Verbascoside; Compound label in the paper: Acteoside
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Mice, Chemicals, and Laboratory Wares (S5); Materials and Methods > Bone Resorption Assay (S27, S28); Results > Acteoside Inhibits Bone Resorption by Macrophages (S101, S103, S104); Figure 3 legend (S163)
pit formation was observed under an optic microscope: pit formation was observed under an optic microscope; comparator: cells cultured with M-CSF and RANKL — Materials and Methods > Bone Resorption Assay (S28); Results > Acteoside Inhibits Bone Resorption by Macrophages (S101, S103, S104)